173 related articles for article (PubMed ID: 35779815)
1. Pharmacological manipulation of Ezh2 with salvianolic acid B results in tumor vascular normalization and synergizes with cisplatin and T cell-mediated immunotherapy.
Qian C; Yang C; Tang Y; Zheng W; Zhou Y; Zhang S; Song M; Cheng P; Wei Z; Zhong C; Wan L; Wang A; Zhao Y; Lu Y
Pharmacol Res; 2022 Aug; 182():106333. PubMed ID: 35779815
[TBL] [Abstract][Full Text] [Related]
2. CU06-1004-Induced Vascular Normalization Improves Immunotherapy by Modulating Tumor Microenvironment
Park S; Oh JH; Park DJ; Zhang H; Noh M; Kim Y; Kim YS; Kim H; Kim YM; Ha SJ; Kwon YG
Front Immunol; 2020; 11():620166. PubMed ID: 33584714
[TBL] [Abstract][Full Text] [Related]
3. TGF-β inhibition combined with cytotoxic nanomedicine normalizes triple negative breast cancer microenvironment towards anti-tumor immunity.
Panagi M; Voutouri C; Mpekris F; Papageorgis P; Martin MR; Martin JD; Demetriou P; Pierides C; Polydorou C; Stylianou A; Louca M; Koumas L; Costeas P; Kataoka K; Cabral H; Stylianopoulos T
Theranostics; 2020; 10(4):1910-1922. PubMed ID: 32042344
[TBL] [Abstract][Full Text] [Related]
4. Tanshinone IIA normalized hepatocellular carcinoma vessels and enhanced PD-1 inhibitor efficacy by inhibiting ELTD1.
Mao D; Wang H; Guo H; Che X; Chen M; Li X; Liu Y; Huo J; Chen Y
Phytomedicine; 2024 Jan; 123():155191. PubMed ID: 38000104
[TBL] [Abstract][Full Text] [Related]
5. EZH2, a prominent orchestrator of genetic and epigenetic regulation of solid tumor microenvironment and immunotherapy.
Sun S; Yu F; Xu D; Zheng H; Li M
Biochim Biophys Acta Rev Cancer; 2022 Mar; 1877(2):188700. PubMed ID: 35217116
[TBL] [Abstract][Full Text] [Related]
6. Tumor vasculature remolding by thalidomide increases delivery and efficacy of cisplatin.
Shen Y; Li S; Wang X; Wang M; Tian Q; Yang J; Wang J; Wang B; Liu P; Yang J
J Exp Clin Cancer Res; 2019 Oct; 38(1):427. PubMed ID: 31656203
[TBL] [Abstract][Full Text] [Related]
7. Inducing vascular normalization: A promising strategy for immunotherapy.
Luo X; Zou W; Wei Z; Yu S; Zhao Y; Wu Y; Wang A; Lu Y
Int Immunopharmacol; 2022 Nov; 112():109167. PubMed ID: 36037653
[TBL] [Abstract][Full Text] [Related]
8. Manipulation of the crosstalk between tumor angiogenesis and immunosuppression in the tumor microenvironment: Insight into the combination therapy of anti-angiogenesis and immune checkpoint blockade.
Zheng W; Qian C; Tang Y; Yang C; Zhou Y; Shen P; Chen W; Yu S; Wei Z; Wang A; Lu Y; Zhao Y
Front Immunol; 2022; 13():1035323. PubMed ID: 36439137
[TBL] [Abstract][Full Text] [Related]
9. Targeting Vascular Endothelial-Cadherin in Tumor-Associated Blood Vessels Promotes T-cell-Mediated Immunotherapy.
Zhao Y; Ting KK; Li J; Cogger VC; Chen J; Johansson-Percival A; Ngiow SF; Holst J; Grau G; Goel S; Muller T; Dejana E; McCaughan G; Smyth MJ; Ganss R; Vadas MA; Gamble JR
Cancer Res; 2017 Aug; 77(16):4434-4447. PubMed ID: 28655790
[TBL] [Abstract][Full Text] [Related]
10. Salvianolic acid B protects human endothelial progenitor cells against oxidative stress-mediated dysfunction by modulating Akt/mTOR/4EBP1, p38 MAPK/ATF2, and ERK1/2 signaling pathways.
Tang Y; Jacobi A; Vater C; Zou X; Stiehler M
Biochem Pharmacol; 2014 Jul; 90(1):34-49. PubMed ID: 24780446
[TBL] [Abstract][Full Text] [Related]
11. Targeting vascular normalization: a promising strategy to improve immune-vascular crosstalk in cancer immunotherapy.
Qian C; Liu C; Liu W; Zhou R; Zhao L
Front Immunol; 2023; 14():1291530. PubMed ID: 38193080
[TBL] [Abstract][Full Text] [Related]
12. LRG1 destabilizes tumor vessels and restricts immunotherapeutic potency.
O'Connor MN; Kallenberg DM; Camilli C; Pilotti C; Dritsoula A; Jackstadt R; Bowers CE; Watson HA; Alatsatianos M; Ohme J; Dowsett L; George J; Blackburn JWD; Wang X; Singhal M; Augustin HG; Ager A; Sansom OJ; Moss SE; Greenwood J
Med; 2021 Nov; 2(11):1231-1252.e10. PubMed ID: 35590198
[TBL] [Abstract][Full Text] [Related]
13. Combining microenvironment normalization strategies to improve cancer immunotherapy.
Mpekris F; Voutouri C; Baish JW; Duda DG; Munn LL; Stylianopoulos T; Jain RK
Proc Natl Acad Sci U S A; 2020 Feb; 117(7):3728-3737. PubMed ID: 32015113
[TBL] [Abstract][Full Text] [Related]
14. The complex role of EZH2 in the tumor microenvironment: opportunities and challenges for immunotherapy combinations.
Qiu J; Sharma S; Rollins RA; Paul TA
Future Med Chem; 2020 Aug; 12(15):1415-1430. PubMed ID: 32723083
[TBL] [Abstract][Full Text] [Related]
15. DTX@VTX NPs synergy PD-L1 immune checkpoint nanoinhibitor to reshape immunosuppressive tumor microenvironment for enhancing chemo-immunotherapy.
Zhang R; Wan Y; Lv H; Li F; Lee CS
J Mater Chem B; 2021 Sep; 9(36):7544-7556. PubMed ID: 34551052
[TBL] [Abstract][Full Text] [Related]
16. Tumor vasculature normalization by orally fed erlotinib to modulate the tumor microenvironment for enhanced cancer nanomedicine and immunotherapy.
Chen Q; Xu L; Chen J; Yang Z; Liang C; Yang Y; Liu Z
Biomaterials; 2017 Dec; 148():69-80. PubMed ID: 28968536
[TBL] [Abstract][Full Text] [Related]
17. Application of PD-1 Blockade in Cancer Immunotherapy.
Wu X; Gu Z; Chen Y; Chen B; Chen W; Weng L; Liu X
Comput Struct Biotechnol J; 2019; 17():661-674. PubMed ID: 31205619
[TBL] [Abstract][Full Text] [Related]
18. Modulating the tumor immune microenvironment with sunitinib malate supports the rationale for combined treatment with immunotherapy.
Li W; Zhan M; Quan YY; Wang H; Hua SN; Li Y; Zhang J; Lu L; Cui M
Int Immunopharmacol; 2020 Apr; 81():106227. PubMed ID: 32078941
[TBL] [Abstract][Full Text] [Related]
19. Immunomodulatory effects of Salvianolic acid B in a spontaneous abortion mouse model.
Wang J; Liu C; Que W; Fujino M; Tong G; Yan H; Li XK
J Reprod Immunol; 2020 Feb; 137():103075. PubMed ID: 31918160
[TBL] [Abstract][Full Text] [Related]
20. Salvianolic acid B and ferulic acid synergistically promote angiogenesis in HUVECs and zebrafish via regulating VEGF signaling.
Chen J; Wang Y; Wang S; Zhao X; Zhao L; Wang Y
J Ethnopharmacol; 2022 Jan; 283():114667. PubMed ID: 34597652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
